Myostatin inhibition for treatment of sarcopenia

Affiliations

¹ Department of Kinesiology and Medical Physics and Applied Radiation Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. Electronic address: Pariseg@mcmaster.ca.
² Department of Kinesiology and Medical Physics and Applied Radiation Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.

Comment

Gianni Parise et al. Lancet Diabetes Endocrinol. 2015 Dec.

. 2015 Dec;3(12):917-8.

doi: 10.1016/S2213-8587(15)00324-1. Epub 2015 Oct 27.

¹ Department of Kinesiology and Medical Physics and Applied Radiation Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. Electronic address: Pariseg@mcmaster.ca.
² Department of Kinesiology and Medical Physics and Applied Radiation Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.

No abstract available

Comment on

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.
Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, Hochberg MC, Ferrari SL, Blain H, Binder EF, Rolland Y, Poiraudeau S, Benson CT, Myers SL, Hu L, Ahmad QI, Pacuch KR, Gomez EV, Benichou O; STEADY Group. Becker C, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):948-57. doi: 10.1016/S2213-8587(15)00298-3. Epub 2015 Oct 27. Lancet Diabetes Endocrinol. 2015. PMID: 26516121 Clinical Trial.